Amgen Inc. vs Takeda Pharmaceutical Company Limited: Examining Key Revenue Metrics

Amgen vs Takeda: Revenue Growth Battle Unveiled

__timestampAmgen Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014200630000001777824000000
Thursday, January 1, 2015216620000001807378000000
Friday, January 1, 2016229910000001732051000000
Sunday, January 1, 2017228490000001770531000000
Monday, January 1, 2018237470000002097224000000
Tuesday, January 1, 2019233620000003291188000000
Wednesday, January 1, 2020254240000003197812000000
Friday, January 1, 2021259790000003569006000000
Saturday, January 1, 2022263230000004027478000000
Sunday, January 1, 2023281900000004263762000000
Monday, January 1, 2024334240000004263762000000
Loading chart...

Unleashing insights

Amgen Inc. vs Takeda: A Revenue Showdown

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's market position and innovation prowess. From 2014 to 2023, Amgen Inc. and Takeda Pharmaceutical Company Limited have showcased contrasting revenue trajectories. Amgen's revenue grew steadily, peaking at approximately $28 billion in 2023, marking a 40% increase from 2014. In contrast, Takeda's revenue surged by over 140% during the same period, reaching a staggering $4.26 trillion in 2023. This dramatic rise reflects Takeda's aggressive expansion and strategic acquisitions. Notably, Takeda's revenue in 2024 remains consistent with 2023, indicating a potential plateau or data gap. As these giants continue to innovate, their financial performance offers a glimpse into the future of global healthcare. Stay tuned as we delve deeper into the strategies driving these impressive figures.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025